APA (7th ed.) Citation

Gamper, E. M., Musoro, J. Z., Coens, C., Stelmes, J., Falato, C., Groenvold, M., . . . Groups, E. G. T. C. G. a. Q. o. L. (2021). Minimally important differences for the EORTC QLQ-C30 in prostate cancer clinical trials. BMC Cancer, 21(1), 1. https://doi.org/10.1186/s12885-021-08609-7

Chicago Style (17th ed.) Citation

Gamper, Eva M., et al. "Minimally Important Differences for the EORTC QLQ-C30 in Prostate Cancer Clinical Trials." BMC Cancer 21, no. 1 (2021): 1. https://doi.org/10.1186/s12885-021-08609-7.

MLA (9th ed.) Citation

Gamper, Eva M., et al. "Minimally Important Differences for the EORTC QLQ-C30 in Prostate Cancer Clinical Trials." BMC Cancer, vol. 21, no. 1, 2021, p. 1, https://doi.org/10.1186/s12885-021-08609-7.